Evidence map›Paper›PMID 38456950›Full record

ArticleJournal of medical systems2024

3D CNN-based Deep Learning Model-based Explanatory Prognostication in Patients  with Multiple Myeloma using Whole-body MRI.

Kento Morita, Shigehiro Karashima, Toshiki Terao, Kotaro Yoshida, Takeshi Yamashita, Takeshi Yoroidaka, Mikoto Tanabe, Tatsuya Imi, Yoshitaka Zaimoku, Akiyo Yoshida and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of medical systems, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Kento MoritaSchool of Electrical, Information and Communication Engineering, Kanazawa University, Kakumamachi, Kanazawa, Ishikawa, 920-1192, Japan.
Shigehiro KarashimaInstitute of Liberal Arts and Science, Kanazawa University, Kanazawa, Japan.
Toshiki TeraoDepartment of Hematology/Oncology, Kameda Medical Center, Kamogawa, Japan.
Kotaro YoshidaDepartment of Radiology, Kanazawa University, Kanazawa, Japan.
Takeshi YamashitaDivision of Internal Medicine, Keiju Kanazawa Hospital, Kanazawa, Japan.
Takeshi YoroidakaDepartment of Hematology, Ishikawa Central Prefectural Hospital, Kanazawa, Japan.
Mikoto TanabeDepartment of Hematology, Ishikawa Central Prefectural Hospital, Kanazawa, Japan.
Tatsuya ImiDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan.
Yoshitaka ZaimokuDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan.
Akiyo YoshidaDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan.
Hiroyuki MaruyamaDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan.
Noriko IwakiDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan.
Go AokiDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan.
Takeharu KotaniDepartment of Hematology, Ishikawa Central Prefectural Hospital, Kanazawa, Japan.
Ryoichi MurataDivision of Internal Medicine, Keiju Kanazawa Hospital, Kanazawa, Japan.
Toshihiro MiyamotoDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan.
Youichi MachidaDepartment of Radiology, Kameda Medical Center, Kamogawa, Japan.
Kosei MatsueDepartment of Hematology/Oncology, Kameda Medical Center, Kamogawa, Japan.
Hidetaka NamboFaculty of Transdisciplinary Sciences for Innovation, Institute of Transdisciplinary Sciences for Innovation, Kanazawa University, Kakumamachi, Kanazawa, Ishikawa, 920-1192, Japan. hide_nambo@staff.kanazawa-u.ac.jp.
Hiroyuki TakamatsuDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan. takamaz@staff.kanazawa-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although magnetic resonance imaging (MRI) data of patients with multiple myeloma (MM) are used to predict prognosis, few reports have applied artificial intelligence (AI) techniques for this purpose. We aimed to analyze whole-body diffusion-weighted MRI data using three-dimensional (3D) convolutional neural networks (CNNs) and Gradient-weighted Class Activation Mapping (Grad-CAM), an explainable AI, to predict prognosis and explore the factors involved in prediction. We retrospectively analyzed the MRI data of a total of 142 patients with MM obtained from two medical centers. We defined the occurrence of progressive disease after MRI evaluation within 12 months as a poor prognosis and constructed a 3D CNN-based deep learning model to predict prognosis. Images from 111 cases were used as the training and internal validation data; images from 31 cases were used as the external validation data. Internal validation of the AI model with stratified 5-fold cross-validation resulted in a significant difference in progression-free survival (PFS) between good and poor prognostic cases (2-year PFS, 91.2% versus [vs.] 61.1%, P = 0.0002). The AI model clearly stratified good and poor prognostic cases in the external validation cohort (2-year PFS, 92.9% vs. 55.6%, P = 0.004), with an area under the receiver operating characteristic curve of 0.804. According to Grad-CAM, the MRI signals of the spleen and bones of the vertebrae and pelvis contributed to prognosis prediction. This study is the first to show that image analysis of whole-body MRI using a 3D CNN without any other clinical data is effective in predicting the prognosis of patients with MM.

Indexed as

Deep LearningMultiple MyelomaArtificial IntelligenceHumansMagnetic Resonance ImagingRetrospective StudiesArtificial intelligenceConvolutional neural networksGradient-weighted class activation mappingMagnetic resonance imagingMultiple myeloma

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.